hit counter
BioLineRx Ltd. (BLRX) Stock News Sentiment & Price - Sentifly
BLRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BioLineRx Ltd. (BLRX)

Israel
Biotechnology
NASDAQ
BLRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BLRX Latest news
PRNewsWire
Neutral
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
2021-11-04 09:15

TEL AVIV, Israel, Nov. 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced an oral presentation and three poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 11-14, 2021 in Atlanta, GA, and virtually.

PRNewsWire
Neutral
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
2021-10-13 08:30

TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT).

Seeking Alpha
Neutral
BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2021 Results - Earnings Call Transcript
2021-08-18 12:10

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2021 Results - Earnings Call Transcript

PRNewsWire
Neutral
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-18 07:00

TEL AVIV, Israel, Aug. 18, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

PRNewsWire
Neutral
BioLineRx to Report Second Quarter 2021 Results on August 18, 2021
2021-08-12 09:30

TEL AVIV, Israel, Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the US markets open.

Seeking Alpha
Neutral
2021 Top Idea Contest - New Ideas
2021-07-29 11:53

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

Seeking Alpha
Neutral
BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
2021-06-30 16:12

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year.

Zacks Investment Research
Negative
New Strong Sell Stocks for June 4th
2021-06-04 09:46

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Seeking Alpha
Neutral
BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 2021 Results - Earnings Call Transcript
2021-05-26 12:01

BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 2021 Results - Earnings Call Transcript

PRNewsWire
Neutral
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-26 07:00

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2021 and provides a corporate update.

Loading more news...